Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-J591 in Progressive Metastatic Castration Resistant Prostate Cancer
NCT04506567Phase 1Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of CONV01-α in prostate cancer (PCa) (9 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Number of Participants With Dose Limiting Toxicity at 6 months, Maximum Tolerated Dose at 6 months and 2 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
CONV01-α
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04506567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506567.